

B1
8. (amended) The genetically manipulated, infectious virus of Claim 7, the genome of which has been modified to encode a heterologous sequence.

IN THE SPECIFICATION

Please amend the paragraph at page 1, lines 5-9, beginning "This application is a continuation . . ." to read as follows:

B2
This application is a continuation of U.S. Application Serial No. 09/161,122, filed September 25, 1998, which claims priority benefit to U.S. Provisional Application Serial No. 60/069, 153, filed September 26, 1997, U.S. Provisional Application Serial No. 60/084,133 filed May 1, 1998, and U.S. Provisional Application Serial No. 60/089,207 filed June 12, 1998, and wherein U.S. Application Serial No. 09/161,122, filed September 25, 1998 also claims the right of priority under 35 U.S.C. § 120 to Application No. 08/316,439, filed September 30, 1994, now U.S. Patent No. 5,840,520, issued November 24, 1998.

REMARKS

Claim 8 has been amended to correct the dependency of the claim.

The application has further been amended to indicate the proper claim to priority. The claim to priority of the parent application, U.S. Application 09/161,122, has been amended in the Amendment filed September 5, 2002 in U.S. Application No. 09/161,122; a copy of the Amendment of September 5, 2002 is submitted herewith (Exhibit D). Upon entry of the present amendment, the earliest date of priority of the present continuation application of U.S. Application No. 09/161,122 is September 30, 1994.

RESTRICTION REQUIREMENT

The Examiner has required restriction of the claims to one of two inventions. In response, Applicants hereby elect to prosecute the claims of Group I (claims 7-12), drawn to recombinant paramyxoviridae viruses, classified in class 435, subclass 235.1.